Literature DB >> 20587518

Runx regulation of sphingolipid metabolism and survival signaling.

Anna Kilbey1, Anne Terry, Alma Jenkins, Gillian Borland, Qifeng Zhang, Michael J O Wakelam, Ewan R Cameron, James C Neil.   

Abstract

The Runx genes (Runx1, 2, and 3) regulate cell fate in development and can operate as either oncogenes or tumor suppressors in cancer. The oncogenic potential of ectopic Runx expression has been shown in transgenic mice that develop lymphoma in potent synergy with overexpressed Myc, and in established fibroblasts that display altered morphology and increased tumorigenicity. Candidate oncogenic functions of overexpressed Runx genes include resistance to apoptosis in response to intrinsic and extrinsic stresses. In a search for gene targets responsible for this aspect of Runx phenotype, we have identified three key enzymes in sphingolipid metabolism (Sgpp1, Ugcg, and St3gal5/Siat9) as direct targets for Runx transcriptional regulation in a manner consistent with survival and apoptosis resistance. Consistent with these changes in gene expression, mass spectrometric analysis showed that ectopic Runx reduces intracellular long-chain ceramides in NIH3T3 fibroblasts and elevated extracellular sphingosine 1 phosphate. Runx expression also opposed the activation of c-Jun-NH(2)-kinase and p38(MAPK), key mediators of ceramide-induced death, and suppressed the onset of apoptosis in response to exogenous tumor necrosis factor alpha. The survival advantage conferred by ectopic Runx could be partially recapitulated by exogenous sphingosine 1 phosphate and was accompanied by reduced phosphorylation of p38(MAPK). These results reveal a novel link between transcription factor oncogenes and lipid signaling pathways involved in cancer cell survival and chemoresistance. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20587518      PMCID: PMC2906707          DOI: 10.1158/0008-5472.CAN-10-0726

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

Review 1.  Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors.

Authors:  S Pyne; N Pyne
Journal:  Pharmacol Ther       Date:  2000-11       Impact factor: 12.310

2.  Molecular cloning and characterization of a lipid phosphohydrolase that degrades sphingosine-1- phosphate and induces cell death.

Authors:  S M Mandala; R Thornton; I Galve-Roperh; S Poulton; C Peterson; A Olivera; J Bergstrom; M B Kurtz; S Spiegel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

3.  Exchange of C(16)-ceramide between phospholipid vesicles.

Authors:  C G Simon; P W Holloway; A R Gear
Journal:  Biochemistry       Date:  1999-11-02       Impact factor: 3.162

4.  Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging.

Authors:  K Blyth; A Terry; N Mackay; F Vaillant; M Bell; E R Cameron; J C Neil; M Stewart
Journal:  Oncogene       Date:  2001-01-18       Impact factor: 9.867

Review 5.  Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation.

Authors:  B Lutterbach; S W Hiebert
Journal:  Gene       Date:  2000-03-21       Impact factor: 3.688

6.  The common retroviral insertion locus Dsi1 maps 30 kilobases upstream of the P1 promoter of the murine Runx3/Cbfa3/Aml2 gene.

Authors:  Monica Stewart; Nancy MacKay; Ewan R Cameron; James C Neil
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.

Authors:  Bryan Linggi; Carsten Müller-Tidow; Louis van de Locht; Ming Hu; John Nip; Hubert Serve; Wolfgang E Berdel; Bert van der Reijden; Dawn E Quelle; Janet D Rowley; John Cleveland; Joop H Jansen; Pier Paolo Pandolfi; Scott W Hiebert
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

8.  The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons.

Authors:  Ditsa Levanon; David Bettoun; Catherine Harris-Cerruti; Eilon Woolf; Varda Negreanu; Raya Eilam; Yael Bernstein; Dalia Goldenberg; Cuiying Xiao; Manfred Fliegauf; Eitan Kremer; Florian Otto; Ori Brenner; Aharon Lev-Tov; Yoram Groner
Journal:  EMBO J       Date:  2002-07-01       Impact factor: 11.598

9.  Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi).

Authors:  Xiaofang Zhang; Juan Li; Zhengang Qiu; Peng Gao; Xiaojuan Wu; Genyin Zhou
Journal:  Cancer Biol Ther       Date:  2009-06-09       Impact factor: 4.742

Review 10.  RUNX: a trilogy of cancer genes.

Authors:  Anders H Lund; Maarten van Lohuizen
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

View more
  20 in total

Review 1.  Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond.

Authors:  Kenneth C Loh; Dianna Baldwin; Julie D Saba
Journal:  Anticancer Agents Med Chem       Date:  2011-11       Impact factor: 2.505

Review 2.  Targeting sphingosine-1-phosphate in hematologic malignancies.

Authors:  Christina E Stevenson; Kazuaki Takabe; Masayuki Nagahashi; Sheldon Milstien; Sarah Spiegel
Journal:  Anticancer Agents Med Chem       Date:  2011-11       Impact factor: 2.505

3.  Genomic promoter occupancy of runt-related transcription factor RUNX2 in Osteosarcoma cells identifies genes involved in cell adhesion and motility.

Authors:  Margaretha van der Deen; Jacqueline Akech; David Lapointe; Sneha Gupta; Daniel W Young; Martin A Montecino; Mario Galindo; Jane B Lian; Janet L Stein; Gary S Stein; Andre J van Wijnen
Journal:  J Biol Chem       Date:  2011-12-09       Impact factor: 5.157

Review 4.  Sphingolipid abnormalities in cancer multidrug resistance: Chicken or egg?

Authors:  Wing-Kee Lee; Richard N Kolesnick
Journal:  Cell Signal       Date:  2017-07-04       Impact factor: 4.315

Review 5.  Sphingolipids and Lymphomas: A Double-Edged Sword.

Authors:  Alfredo Pherez-Farah; Rosa Del Carmen López-Sánchez; Luis Mario Villela-Martínez; Rocío Ortiz-López; Brady E Beltrán; José Ascención Hernández-Hernández
Journal:  Cancers (Basel)       Date:  2022-04-19       Impact factor: 6.575

6.  The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion.

Authors:  Mamadou Keita; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  Cell Cycle       Date:  2013-02-26       Impact factor: 4.534

7.  Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.

Authors:  Tomohiro Hirade; Mariko Abe; Chie Onishi; Takeshi Taketani; Seiji Yamaguchi; Seiji Fukuda
Journal:  Int J Hematol       Date:  2015-11-21       Impact factor: 2.490

8.  Genome-wide screening in human growth plates during puberty in one patient suggests a role for RUNX2 in epiphyseal maturation.

Authors:  Joyce Emons; Bas E Dutilh; Eva Decker; Heide Pirzer; Carsten Sticht; Norbert Gretz; Gudrun Rappold; Ewan R Cameron; James C Neil; Gary S Stein; Andre J van Wijnen; Jan Maarten Wit; Janine N Post; Marcel Karperien
Journal:  J Endocrinol       Date:  2011-02-09       Impact factor: 4.286

9.  Genome wide analysis of acute myeloid leukemia reveal leukemia specific methylome and subtype specific hypomethylation of repeats.

Authors:  Marwa H Saied; Jacek Marzec; Sabah Khalid; Paul Smith; Thomas A Down; Vardhman K Rakyan; Gael Molloy; Manoj Raghavan; Silvana Debernardi; Bryan D Young
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

10.  Tumor Suppressor WWOX inhibits osteosarcoma metastasis by modulating RUNX2 function.

Authors:  Sara Del Mare; Rami I Aqeilan
Journal:  Sci Rep       Date:  2015-08-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.